BioArctic
BioArctic AB is a Swedish biopharmaceutical company that develops biological therapeutics targeting neurodegenerative central nervous system disorders. The company focuses on research and development of disease-modifying antibody therapies for conditions such as Alzheimer's disease and Parkinson's disease. Revenue is primarily driven by upfront licensing fees, development milestone payments, and ongoing sales royalties from global pharmaceutical commercial partners. Its target end market consists of global healthcare providers, hospitals, and patients affected by progressive neurodegenerative illnesses. The company's most prominent product is lecanemab, a disease-modifying Alzheimer's treatment commercialized through a partnership with Eisai. BioArctic maintains a prominent position within the Nordic biotechnology sector due to its proprietary antibody technology platforms. The company is headquartered in Stockholm, Sweden, and its equity is listed on Nasdaq Stockholm.
26 of the funds FundTelligence covers report a position in BioArctic.
- Legal name
- BioArctic AB
- Sector
- Health Care
- Country
- Sweden
- Funds holding it
- 26
- Exposure themes
- Ageing & Longevity, Age-Related Disease, Neurodegeneration
Funds holding BioArctic
- Lannebo Sverige Plus — Lannebo · 4.59 % (full portfolio disclosed, June 2026)
- Lannebo Sverige — Lannebo · 4.57 % (full portfolio disclosed, June 2026)
- Indecap Guide Q30 — Indecap · 3.69 % (full portfolio disclosed, June 2026)
- Simplicity Småbolag Sverige — Simplicity · 2.33 % (full portfolio disclosed, June 2026)
- Nordea Nordic Small Cap — Nordea Funds · 1.54 % (full portfolio disclosed, July 2026)
- Nordea Nordic Small Cap Fund — Nordea Funds · 1.54 % (full portfolio disclosed, July 2026)
- Lannebo Sweden Micro Cap — Lannebo · 1.22 % (full portfolio disclosed, June 2026)
- Indecap Sverige — Indecap · 0.86 % (full portfolio disclosed, June 2026)
Showing the 8 largest of 26 funds holding it.